An AllTrials project

NCT06596694: An ongoing trial by Merck Sharp & Dohme LLC

This trial is ongoing. It must report results 3 years, 11 months from now.

Full data

Full entry on ClinicalTrials.gov NCT06596694
Title A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Nov. 3, 2024
Completion date Dec. 7, 2028
Required reporting date Dec. 7, 2029, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Dec. 12, 2025
Days late None